Data from the Swiss Clinical Quality Management cohort revealed that patients with AS who were TNF inhibitor users, and who achieved clinical remission (ankylosing spondylitis disease activity score (ASDAS) < 1.3) showed less progression of mSASSS than TNF inhibitor users with higher ASDAS scores (ASDAS > 1.3). The gene discussed is TNF; the disease is ankylosing spondylitis.